about
Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studiesThe Role of microRNAs in the Diagnosis and Treatment of Pancreatic AdenocarcinomaHave lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomasKRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell CulturesPancreatic cancer and liver metastases: state of the art.Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patientsProfiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.Current and future systemic treatment options in metastatic pancreatic cancer.Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancerCirculating DNA and Micro-RNA in Patients with Pancreatic Cancer.A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancerPhase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancerNovel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancerTargeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis.Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.Advanced-stage pancreatic cancer: therapy options.Intervention on toll-like receptors in pancreatic cancer.ALK expression is absent in pancreatic ductal adenocarcinoma.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature reviewSynergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxiaInhibitory effect of geraniol in combination with gemcitabine on proliferation of BXPC-3 human pancreatic cancer cells.Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.
P2860
Q22305489-CC68C59F-EE9C-4F55-9005-DC40F6ECFE7AQ26744298-E3762A18-C553-4A74-A2F5-924CCA0742EBQ26747695-CBFA26FC-48EB-4B5E-B521-89796924BEFAQ26751724-8E56C169-66DB-475A-8736-7353EE007534Q27852101-0670E563-5DAE-43C6-8648-1CC13A05BDB9Q28550991-0A76711A-BFD8-42C8-802A-8FBC1F92D357Q30241486-1650C551-2010-4C33-B9AC-B6F57613C9ECQ31052763-18E631BF-9F93-47D5-AE21-81917905D669Q33442676-10F957DC-E190-4B86-8359-FC684836E09BQ33630872-918867D2-4026-4FF6-A24E-0BD559E661FDQ33730022-50A624AD-196E-48A9-9DE9-D52078B7CAA1Q33774197-849A1730-0B75-440D-AB69-78805D04DD14Q33877459-9D40EA48-EAD9-43AE-88B0-4D0DA2F366A3Q33948033-FB8E2658-06DE-4A90-BF13-FB9AD21C3B36Q34067863-48F4B0C7-CA21-4752-87FD-8ED4071A2D3BQ34123654-E5645112-63E3-4AA0-A9A1-DD831BD1EE59Q34253198-DC76D46C-4E6D-4452-A948-F1CB1179D50BQ34871953-568C865D-0AE5-4A0C-AB58-FC259E485978Q34996501-CD474BD5-CD50-4A9F-8FCD-250562F149C1Q35320095-31A27932-0064-4E1F-A5D3-94AAF269EBF1Q35674826-5A060A78-6E7D-4758-9FEB-7E6C72524B00Q35828060-EC8370B6-A0FB-4381-A14B-10CA37853728Q35946922-15E2DB96-0D27-4A13-9384-C2906155BF32Q36524171-C418F258-202A-49EA-892D-28624227A0DAQ36663677-A1C15450-EC5F-4895-9D9C-79B07FF9F73DQ36886874-1EC0B947-C3A5-4422-B5D4-9A92E5096130Q36889709-5127806C-0298-4C4B-8276-E8E4FF28930CQ37010760-97E866F4-4143-495C-B0BB-7179A67D51AFQ37032865-CEB6A4C8-EEF2-4E82-81C9-DB1CA99437F7Q37093547-9BA6884D-5930-4969-A42A-25295CAFF53EQ37317518-49474324-02B8-4620-8326-BF5A2AA527C5Q37448070-2A0421F7-91DD-4563-AFCF-3D53284E24F0Q38102914-B7F52649-B1A1-4103-A385-90C16D958522Q38219023-C5BDEABF-EC4A-4052-9D5C-C503B19D53E3Q38390927-A643429D-2B8A-4170-9FF3-EFAAD4B903CBQ38591066-25B6B280-2446-4920-BA53-4865F2CFBBEFQ38652339-265BB22A-7CD9-47F4-91CC-5260FEC0C87AQ39068039-FC9BAF42-3827-4D02-83F6-51A955AD5697Q39134968-598B50CD-61C7-463E-B11C-6980DBEEA674Q39216345-906EFDE6-BE43-442F-9977-447F29C84871
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systemic treatment of advanced pancreatic cancer.
@en
Systemic treatment of advanced pancreatic cancer.
@nl
type
label
Systemic treatment of advanced pancreatic cancer.
@en
Systemic treatment of advanced pancreatic cancer.
@nl
prefLabel
Systemic treatment of advanced pancreatic cancer.
@en
Systemic treatment of advanced pancreatic cancer.
@nl
P2093
P1476
Systemic treatment of advanced pancreatic cancer.
@en
P2093
Michael Haas
Stefan Boeck
Volker Heinemann
P304
P356
10.1016/J.CTRV.2011.12.004
P577
2012-01-04T00:00:00Z